Document is current
Any future updates will be listed below
-
Authors
Addeo, Alfredo http://orcid.org/0000-0003-0988-0828
Friedlaender, Alex
Giovannetti, Elisa http://orcid.org/0000-0002-7565-7504
Russo, Alessandro http://orcid.org/0000-0002-3365-1972
de Miguel-Perez, Diego http://orcid.org/0000-0002-2822-4466
Arrieta, Oscar
Cardona, Andres F. http://orcid.org/0000-0003-3525-4126
Rolfo, Christian http://orcid.org/0000-0002-5109-0267
- License Information
-
More Information
Article History
Accepted: 24 April 2021
First Online: 4 November 2021
Declarations
:
: Dr. Friedlander reports personal fees from Bristol-Myers Squibb, Roche, Pfizer, Merck Sharp and Dohme, and Astellas outside the submitted work; Dr. Addeo reports personal fees from Bristol-Myers Squibb, AstraZeneca, Roche, Pfizer, Merck Sharp and Dohme, and Boehringer-Ingelheim; Dr. Russo reports personal fees for attending advisory board meetings from Astra Zeneca, MSD, and Novartis outside the submitted work. Dr. Arrieta reports personal fees from Pfizer, grants and personal fees from AstraZeneca, grants, personal fees from Boehringer-Ingelheim, personal fees from Lilly, personal fees from Merck, personal fees from Bristol-Myers Squibb, and grants and personal fees from Roche, outside the submitted work; Dr. Cardona discloses financial research support from Merck Sharp & Dohme, Boehringer-Ingelheim, Roche, Bristol-Myers Squibb, Foundation Medicine, Roche Diagnostics, Thermo Fisher, Broad Institute, BioNTech, Amgen, Flatiron Health, Teva Pharma, Rochem Biocare, Bayer, INQBox, and The Foundation for Clinical and Applied Cancer Research – FICMAC. Additionally, he was linked and received honoraria as advisor, participated in speakers’ bureau, and gave expert testimony to EISAI, Merck Serono, Janssen Pharmaceutical, Merck Sharp & Dohme, Boehringer-Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly, Guardant Health, Illumina, and Foundation for Clinical and Applied Cancer Research – FICMAC; Dr. Rolfo reports grants for Lung Cancer Research Foundation-Pfizer Grant 2019 NHI U54 grant (Project co-leader). He has received personal fees for attending advisory board with Inivata, ArcherDx, MD Serono, BMS, Novartis, and Boston Pharmaceuticals; fee for speaking bureau: MSD, Astra Zeneca, Roche. Non-financial conflict included research collaboration: Guardant Health. The other authors have non-financial relationship to disclose.
Free to read: This content has been made available to all.
